GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Archived. This submission is more than a year old. Votes and new comments are closed, and some of the advice in it may have been superseded — check the community wiki for the current version.
2.3k
c/bpc157·posted 1 year ago by u/karim_hartmann

tendon: what the trials say vs what this community says

Question Clean Column ×7 Receipts ×3

tendon: what the trials say vs what this community says — a position I have arrived at slowly and would like tested.

The evidence base, described honestly, which almost no summary of it does.

The published literature is overwhelmingly preclinical and largely in rodent models. The individual papers are generally more modest in their claims than the summaries that circulate. Human clinical trial evidence for the claims most often repeated in these threads is very limited.

That is not an argument that nothing is happening in the preclinical work — some of it is genuinely interesting. It is an argument that the distance between "this happened in a rodent model" and "this will happen in a person" is large, uncertain, and crossed silently in nearly every confident post on this board, including some of mine from two years ago.

Purity by area percent tells you the sample is homogeneous. Mass spectrometry tells you what the homogeneous thing is. For a short peptide, the second question is the one worth paying for.

It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.

If somebody has the same thing measured a different way, post it next to mine and we will see whether they agree.

3,501 up / 1,230 down74% upvoted68 commentsid 1ys7f222 May 2025

68 comments

30 in this archive, depth 6

best — the order this archive was captured in

u/enzo_ferrari171 points·1 year ago

Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.

replysharereportpermalink
u/hamza_weiss135 points·1 year ago

Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation.

Agreed — and the preclinical to clinical gap is where nearly all the overclaiming happens.

replysharereportpermalink
[removed]102 points·1 year ago

[removed by moderator]

replysharereportpermalink
u/karim_hartmannOP74 points·1 year ago

That is a purity figure, not an identity confirmation. Two different tests and only one answers the question asked.

replysharereportpermalink
u/bruno_dumitru100 points·1 year ago

Careful. Regulatory status differs by jurisdiction and has changed; a confident global statement is going to be wrong somewhere.

replysharereportpermalink
u/karim_hartmannOP53 points·1 year ago·edited

Correcting myself: I said the regulatory position had not changed and in that jurisdiction it has.

replysharereportpermalink
u/viktor_laurent19 points·1 year ago

Correction: that study was in rodents. Worth stating explicitly since the thread has been reading it as clinical.

replysharereportpermalink
u/neha_rahimi56 points·1 year ago

Paid for identity confirmation rather than just purity for the first time here. Worth it, and it is not the default on most certificates.

replysharereportpermalink
u/sofia_ferreira39 points·1 year ago

That claim traces back to a single preclinical paper that says something considerably narrower.

replysharereportpermalink
u/isabela_nilsen11 points·1 year ago

Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.

replysharereportpermalink
u/karim_hartmannOP8 points·1 year ago

Do you have the mass spectrum?

replysharereportpermalink
u/honest_syringe3 points·1 year ago

no clinical trial has established what these threads assert

replysharereportpermalink
u/taper_off_tabitha31 points·1 year ago

pentadecapeptide, fifteen residues, and the sequence is public

replysharereportpermalink
u/rekha_mwangi9 points·1 year ago

Same. Solution stability is the practical question and almost nobody asks it.

replysharereportpermalink
u/vikram_mbeki13 points·1 year ago·edited

Right, and regulatory status has genuinely moved in several jurisdictions. Answers from three years ago may be wrong now.

replysharereportpermalink
u/honest_syringe-13 points·1 year ago

the human evidence is thin and the rodent evidence is not

replysharereportpermalink
u/baseline_drifteranalytical9 points·1 year ago

Went and read the primary rodent papers after arguing about a summary for a week. They are much narrower than the threads suggest.

replysharereportpermalink
u/kaplan_meier_kim7 points·1 year ago

Bought small, tested identity first, and only then thought about anything else. That order felt right.

replysharereportpermalink
u/enzo_fonseca10 points·1 year ago

regulatory status varies by jurisdiction and it has moved recently

replysharereportpermalink
u/ilias_steiner5 points·1 year ago

identity, quantity, stability — three separate questions

replysharereportpermalink
u/asks_dumb_questions50 points·1 year ago

Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.

replysharereportpermalink
u/batch_number_bertievetting11 points·1 year ago

most of the claims here trace to the same handful of rodent papers

replysharereportpermalink
u/aurel_boateng29 points·1 year ago·edited

The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.

replysharereportpermalink
u/tb500_tangent24 points·1 year ago·edited

Disagree — that is a rodent study and you are stating it as a human effect. The distance between those is the entire argument.

replysharereportpermalink
u/slow_logbook_ftw8 points·1 year ago

Cosigning that the papers are more modest than the summaries of them. That is true across this whole site and especially here.

replysharereportpermalink
u/sequence_checkerMOD16 points·1 year ago

Added a jurisdiction tag to the regulatory question. The answer differs and has changed.

replysharereportpermalink
u/ilias_steiner11 points·1 year ago

read the actual papers, they are more modest than the summaries

replysharereportpermalink
u/joaquin_ivaturi8 points·1 year ago

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

replysharereportpermalink
u/enzo_danquah4 points·1 year ago·edited

I would not extrapolate a mechanism from a model system to a person in one step, which is what that comment does.

Adding the standing caveat — research material is not approved for human use, wherever you are.

replysharereportpermalink
u/ice_pack_auditcold chain6 points·1 year ago

Has anyone posted an independent result on that batch?

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/bpc157

BPC-157 as it actually is: a pentadecapeptide with a genuinely interesting rodent tendon-and-gut literature, near-zero controlled human data, a naming and sequence mess in the supply chain, and a regulatory status that changed sharply in several countries.

35kmembers
62submissions
Mar 2024created
submissions / month, last year
Sponsored

Sigma-Aldrich Standards

Certified reference materials for peptide identity and purity work.

sigmaaldrich.com
c/bpc157 rules
  1. Research use only. No human protocols, no injection instructions.
  2. Rodent data must be labelled as rodent data in the body.
  3. Sequence and naming claims need the actual sequence.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.